+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
TKI for Chronic Myeloid Leukemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
TKI for Chronic Myeloid Leukemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

TKI for Chronic Myeloid Leukemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6079176
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The treatment landscape for Chronic Myeloid Leukemia (CML) has undergone a profound transformation over the past two decades, driven by breakthroughs in tyrosine kinase inhibitor (TKI) therapies. What was once a fatal hematologic malignancy now offers patients the prospect of long-term remission and improved quality of life. In this executive summary, we introduce the major advances that have redefined standard of care, highlight the strategic shifts reshaping commercial dynamics, and set the stage for actionable guidance intended to empower decision-makers in both established and emerging markets.

CML management has evolved from non-specific cytotoxic regimens to precision-targeted TKIs that disrupt BCR-ABL signaling. As multiple generations of inhibitors gain regulatory approvals and combination approaches emerge, stakeholders face a more complex competitive environment. At the same time, policy changes, including the United States’ new tariff framework for pharmaceuticals, are altering cost structures and prompting companies to revisit sourcing strategies.

This summary synthesizes key insights across nine critical segmentation dimensions, regional performance clusters, and leading industry players. By drawing these threads together, we provide a cohesive overview of current market drivers, competitive positioning, and regulatory headwinds. Ultimately, the goal is to equip oncology executives, portfolio managers, and policy analysts with a clear understanding of opportunities and risks in the CML TKI arena.

Transformative Shifts Redefining CML Treatment and Access

The landscape of CML therapeutics has shifted dramatically as molecular insights have accelerated drug development pathways. The first-generation TKI laid the groundwork by delivering targeted efficacy, but subsequent generations have built upon that success with enhanced potency, improved safety profiles, and resistance-overcoming capabilities. Second-generation agents addressed key mutational escapes, while third-generation inhibitors further expanded options for patients with T315I and compound mutations.

Simultaneously, combination therapies blending TKIs with chemotherapy or immunotherapy have entered clinical practice, reflecting a paradigm shift toward multi-modal intervention. These regimens aim to eradicate residual disease, deepen molecular responses, and potentially pave the way for treatment-free remission. Advances in companion diagnostics have enabled real-time monitoring of BCR-ABL transcript levels, guiding dose adjustments and minimizing toxicity.

Beyond molecular innovation, digital health solutions and telemedicine platforms have enhanced patient adherence monitoring, particularly in rural and underserved regions. Real-world evidence initiatives are informing label expansions and reimbursement decisions, while value-based contracting models are gaining traction in response to budgetary pressures. Taken together, these transformative shifts underscore a more dynamic, patient-centric ecosystem that rewards agility, data integration, and cross-sector collaboration.

Assessing the 2025 U.S. Tariff Impact on TKI Supply Chains

In 2025, the United States implemented revised tariff schedules affecting key imported active pharmaceutical ingredients and finished TKI formulations. These adjustments have introduced a range of cost implications across the value chain. Manufacturers reliant on overseas intermediates are experiencing higher procurement costs, which in turn place pressure on drug pricing negotiations with payers.

Pharmaceutical companies are responding by diversifying their supplier base, investing in domestic manufacturing capabilities, and leveraging bilateral trade agreements to mitigate duties. Parallel import strategies have gained traction as firms seek tariff-free channels for generic and branded TKIs. Meanwhile, contract manufacturing organizations are optimizing regional footprints to balance compliance with cost efficiency.

Despite initial margin compression, some innovators have capitalized on the policy shift by localizing high-value synthesis steps, thereby creating domestic job opportunities and strengthening supply-chain resilience. Payers and health systems, keen to manage total cost of care, are increasingly evaluating life-cycle management programs-such as authorized generics and patient assistance initiatives-to preserve access without compromising treatment outcomes.

In-Depth Segmentation Insights Across Nine Dimensions

A granular view of the CML TKI market reveals distinct growth drivers and adoption patterns across therapeutic class, patient demographics, treatment settings, end users, route of administration, line of treatment, dosage forms, molecular targets, and development stages.

Analysis of therapeutic class shows that first-generation inhibitors continue to serve as backbone therapies in certain regions, while second-generation agents capture a growing share due to superior efficacy in resistant disease. Third-generation TKIs are emerging as critical options for T315I mutations. Meanwhile, combination therapies with chemotherapy offer a deep-molecular-response strategy, and immunotherapy pairings are accelerating clinical interest by enhancing immune-mediated clearance of leukemic clones.

Patient demographics influence prescribing behavior: adult populations drive base utilization volumes, geriatrics demand tailored safety profiles, and pediatric programs prioritize long-term tolerability. Gender differences reveal comparable response rates, but variations in adverse-event profiles inform dose optimization. Insurance coverage patterns-spanning private, public, and uninsured cohorts-shape access and patient assistance program design.

Treatment settings illustrate channel evolution. Hospital pharmacies remain central for initial dosing and monitoring, while online pharmacies facilitate refill compliance, and retail outlets support convenient access. End users span contract manufacturing organizations that underpin supply-chain scalability, healthcare providers delivering frontline care, pharmaceutical companies steering R&D, and research institutes advancing novel targets.

Route of administration underscores patient preference for oral dosing, though intravenous infusions maintain relevance for acute interventions. Line-of-treatment dynamics position first-line protocols as cost-effective entry points, second-line regimens for suboptimal responders, and third-line and beyond for refractory cases. Dosage forms concentrate on capsules and tablets, with formulation science improving bioavailability.

In terms of molecular target, BCR-ABL inhibitors constitute the core class, while multi-tyrosine kinase inhibitors broaden spectrum activity against co-activated pathways. Finally, the development pipeline spans discovery and preclinical research, through clinical trials-phase I, phase II, and phase III-where combination regimens and next-generation molecules dominate the R&D agenda.

Key Regional Insights Shaping Market Access and Adoption

Regional performance in the CML TKI market exhibits marked differences driven by healthcare infrastructure, regulatory frameworks, and economic development. In the Americas, robust reimbursement pathways and established oncology networks support rapid uptake of novel agents. Value-based agreements are increasingly common, enabling access to high-cost therapies while aligning payment with real-world outcomes.

Europe, the Middle East & Africa present a heterogeneous landscape. In Western Europe, centralized approval processes and health technology assessments streamline market entry, whereas emerging markets in Eastern Europe and MENA emphasize cost containment and generic competition. Reimbursement negotiations vary widely, with some countries adopting risk-sharing models tied to molecular response milestones.

Asia-Pacific showcases a spectrum from mature markets with comprehensive coverage to developing economies where out-of-pocket costs remain significant. Government-sponsored insurance schemes in select countries are expanding TKI accessibility, while local manufacturing hubs are leveraging favorable trade policies to lower prices. Cross-border collaborations and clinical trial networks are also flourishing, enhancing regional contributions to global R&D efforts.

Competitive and Innovation Landscape: Leading Players

Leading innovators and strategic partnerships are central to advancing the CML TKI market. ABL Bio, Inc. has focused on next-generation molecules targeting resistant mutations, while Ariad Pharmaceuticals, Inc., as part of Takeda, leverages global commercialization capabilities. Astellas Pharma Inc. distinguishes itself through combination immunotherapy trials, and Bristol-Myers Squibb Company explores multi-kinase inhibition profiles.

ChemGenex Pharmaceuticals Ltd, now integrated within Cephalon, Inc., continues to optimize its formulation expertise through high-purity synthesis processes. Fusion Pharmaceuticals Inc. is pioneering radionuclide-conjugated TKIs for targeted cytotoxicity. Incyte Corporation’s collaborations with biotechs accelerate novel candidate identification, whereas Novartis AG maintains leadership via diverse TKI portfolios and life-cycle management programs.

Pfizer Inc. and Roche Holding AG deploy comprehensive real-world evidence platforms to support label expansions and pricing negotiations. Sun Pharma Advanced Research Company Ltd. (SPARC) capitalizes on cost-effective production models and emerging market distribution networks. These companies collectively drive innovation, forge alliances, and refine commercialization strategies to meet evolving clinical and payer demands.

Actionable Recommendations for CML TKI Market Leaders

Industry leaders should prioritize three strategic imperatives. First, integrate end-to-end supply-chain resilience by diversifying sourcing channels and investing in regional manufacturing to mitigate tariff and geopolitical risks. Second, expand value-based contracting frameworks tied to molecular response metrics, aligning stakeholder incentives and facilitating premium pricing for high-value therapies. Third, accelerate precision-medicine initiatives by partnering with digital health and diagnostic firms to deliver personalized dosing algorithms and adherence-monitoring tools.

Additionally, companies must deepen engagement with patient advocacy groups and payers to co-design access programs that address affordability challenges, especially in underinsured populations. Cross-sector collaborations-spanning academia, biotech, and contract research organizations-will be essential to propel next-generation TKI combinations and novel molecular targets through the clinical pipeline. Finally, a proactive approach to regulatory agility, leveraging real-world evidence and adaptive trial designs, can reduce time to approval and optimize product launch sequences.

Conclusion: Charting the Future of CML Therapy

In summary, the CML TKI market is at a pivotal juncture marked by sophisticated molecular therapies, evolving reimbursement landscapes, and strategic supply-chain realignments. Stakeholders who navigate the nine segmentation dimensions with precision, adapt to regional nuances, and forge partnerships across the ecosystem will secure leadership positions. Embracing data-driven decision-making, agile commercialization models, and collaborative R&D strategies will unlock sustainable growth and ensure continued improvements in patient outcomes.

Market Segmentation & Coverage

This research report categorizes the TKI for Chronic Myeloid Leukemia Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Combination Therapies
    • With Chemotherapy
    • With Immunotherapy
  • First-Generation TKI
  • Second-Generation TKI
  • Third-Generation TKI
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
  • Health Insurance Status
    • Private Insurance
    • Public Insurance
    • Uninsured
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Contract Manufacturing Organizations
  • Healthcare Providers
  • Pharmaceutical Companies
  • Research Institutes
  • Intravenous
  • Oral
  • First-Line
  • Second-Line
  • Third-Line And Beyond
  • Capsules
  • Tablets
  • BCR-ABL Inhibitors
  • Multi-Tyrosine Kinase Inhibitors
  • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
  • Discovery
  • Preclinical

This research report categorizes the TKI for Chronic Myeloid Leukemia Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the TKI for Chronic Myeloid Leukemia Market to delves into recent significant developments and analyze trends in each of the following companies:

  • ABL Bio, Inc.
  • Ariad Pharmaceuticals, Inc. (A subsidiary of Takeda Pharmaceutical Company Limited)
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • ChemGenex Pharmaceuticals Ltd (Now part of Cephalon, Inc.)
  • Fusion Pharmaceuticals Inc.
  • Incyte Corporation
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharma Advanced Research Company Ltd. (SPARC)

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. TKI for Chronic Myeloid Leukemia Market, by Therapeutic Class
8.1. Introduction
8.2. Combination Therapies
8.2.1. With Chemotherapy
8.2.2. With Immunotherapy
8.3. First-Generation TKI
8.4. Second-Generation TKI
8.5. Third-Generation TKI
9. TKI for Chronic Myeloid Leukemia Market, by Patient Demographics
9.1. Introduction
9.2. Age Group
9.2.1. Adult
9.2.2. Geriatric
9.2.3. Pediatric
9.3. Gender
9.3.1. Female
9.3.2. Male
9.4. Health Insurance Status
9.4.1. Private Insurance
9.4.2. Public Insurance
9.4.3. Uninsured
10. TKI for Chronic Myeloid Leukemia Market, by Treatment Settings
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. TKI for Chronic Myeloid Leukemia Market, by End Users
11.1. Introduction
11.2. Contract Manufacturing Organizations
11.3. Healthcare Providers
11.4. Pharmaceutical Companies
11.5. Research Institutes
12. TKI for Chronic Myeloid Leukemia Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Oral
13. TKI for Chronic Myeloid Leukemia Market, by Line Of Treatment
13.1. Introduction
13.2. First-Line
13.3. Second-Line
13.4. Third-Line And Beyond
14. TKI for Chronic Myeloid Leukemia Market, by Dosage Forms
14.1. Introduction
14.2. Capsules
14.3. Tablets
15. TKI for Chronic Myeloid Leukemia Market, by Molecular Target
15.1. Introduction
15.2. BCR-ABL Inhibitors
15.3. Multi-Tyrosine Kinase Inhibitors
16. TKI for Chronic Myeloid Leukemia Market, by Development Stage
16.1. Introduction
16.2. Clinical Trials
16.2.1. Phase I
16.2.2. Phase II
16.2.3. Phase III
16.3. Discovery
16.4. Preclinical
17. Americas TKI for Chronic Myeloid Leukemia Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific TKI for Chronic Myeloid Leukemia Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa TKI for Chronic Myeloid Leukemia Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. ABL Bio, Inc.
20.3.2. Ariad Pharmaceuticals, Inc. (A subsidiary of Takeda Pharmaceutical Company Limited)
20.3.3. Astellas Pharma Inc.
20.3.4. Bristol-Myers Squibb Company
20.3.5. ChemGenex Pharmaceuticals Ltd (Now part of Cephalon, Inc.)
20.3.6. Fusion Pharmaceuticals Inc.
20.3.7. Incyte Corporation
20.3.8. Novartis AG
20.3.9. Pfizer Inc.
20.3.10. Roche Holding AG
20.3.11. Sun Pharma Advanced Research Company Ltd. (SPARC)
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET MULTI-CURRENCY
FIGURE 2. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET MULTI-LANGUAGE
FIGURE 3. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 24. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY WITH IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY FIRST-GENERATION TKI, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY SECOND-GENERATION TKI, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THIRD-GENERATION TKI, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PUBLIC INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY UNINSURED, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THIRD-LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MULTI-TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 102. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 103. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 104. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 106. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 107. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 108. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 109. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 110. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 113. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 114. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 115. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 119. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 121. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 122. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 126. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 128. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 174. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 175. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 176. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 177. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 179. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 180. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 181. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 182. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 185. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 186. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 187. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 188. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 189. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 190. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 191. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 193. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 194. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 195. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 196. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 199. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 200. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 201. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 216. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 217. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 218. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 219. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 220. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 221. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 222. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 223. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 224. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 226. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 227. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 228. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 229. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 242. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULAR TARGET, 2018-2030 (USD MILLION)
TABLE 284. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 285. SOUTH KOREA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 288. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HEALTH INSURANCE STATUS, 2018-2030 (USD MILLION)
TABLE 292. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY TREATMENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 293. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 294. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. TAIWAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY LINE OF TREATMENT, 2018-2030 (USD MILLION)

Companies Mentioned

  • ABL Bio, Inc.
  • Ariad Pharmaceuticals, Inc. (A subsidiary of Takeda Pharmaceutical Company Limited)
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • ChemGenex Pharmaceuticals Ltd (Now part of Cephalon, Inc.)
  • Fusion Pharmaceuticals Inc.
  • Incyte Corporation
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharma Advanced Research Company Ltd. (SPARC)

Methodology

Loading
LOADING...

Related Topics

Related Reports

Chronic Myelogenous Leukemia Therapeutics Market by Treatment Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Chronic Myelogenous Leukemia Therapeutics Market by Treatment Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Chronic Myeloid Leukemia - Pipeline Insight, 2025 - Product Image

Chronic Myeloid Leukemia - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Leukemia Therapeutics Market Report 2025 - Product Image

Leukemia Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Acute Myeloid Leukemia Market Report 2025 - Product Image

Acute Myeloid Leukemia Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Leukemia Therapeutics - Global Strategic Business Report - Product Image

Leukemia Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.